v3.26.1
Basis of Presentation and Significant Accounting Policies - Summary of Significant Expense Categories Regularly Reviewed CODM (Details) - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Significant Accounting Policies [Line Items]    
Collaboration revenue $ 251,147 $ 257,884
Research and development expenses:    
Total research and development expenses [1] 4,096,580 5,214,076
General and administrative expenses:    
Employee related costs 731,673 684,083
Stock-based compensation 1,759,868 695,393
Other general and administrative expenses [2] 1,290,436 1,334,414
Total general and administrative expenses 3,781,977 2,713,890
In-process research and development 10,000  
Depreciation 2,807 6,840
Other income (433,227) (370,165)
Net loss (7,206,990) (7,306,757)
Clinical product candidates    
Research and development expenses:    
Total research and development expenses [1] 2,801,890  
Preclinical product candidates    
Research and development expenses:    
Total research and development expenses [1]   4,022,376
Sponsored research    
Research and development expenses:    
Total research and development expenses [1] 96,250 202,410
Internal research and development expenses, including stock-based compensation    
Research and development expenses:    
Total research and development expenses [1] $ 1,198,440 $ 989,290
[1] External research and development expenses include: fees paid to CROs, CMOs and research laboratories, process development, manufacturing and clinical development activities. Any internal research and development expenses associated with clinical product candidates are captioned as internal research and development expenses.
[2] Other general and administrative costs include professional fees, investor relation costs, taxes, licenses, and insurance.